Title : Bezafibrate for the treatment of primary sclerosing cholangitis.

Pub. Date : 2010 Jul

PMID : 20127368






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS: Bezafibrate (400 mg/day) was orally administered to 7 consecutive patients with PSC, and we analyzed their clinical features and the drug efficacy in terms of the effect on hepatobiliary enzymes, including ALP, gamma-glutamyl transpeptidase (gamma-GTP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) after 6 months. Bezafibrate solute carrier family 17 member 5 Homo sapiens
2 METHODS: Bezafibrate (400 mg/day) was orally administered to 7 consecutive patients with PSC, and we analyzed their clinical features and the drug efficacy in terms of the effect on hepatobiliary enzymes, including ALP, gamma-glutamyl transpeptidase (gamma-GTP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) after 6 months. Bezafibrate solute carrier family 17 member 5 Homo sapiens